MX9306147A - Composicion farmaceutica para inhibir el crecimiento de celulas tumorales. - Google Patents

Composicion farmaceutica para inhibir el crecimiento de celulas tumorales.

Info

Publication number
MX9306147A
MX9306147A MX9306147A MX9306147A MX9306147A MX 9306147 A MX9306147 A MX 9306147A MX 9306147 A MX9306147 A MX 9306147A MX 9306147 A MX9306147 A MX 9306147A MX 9306147 A MX9306147 A MX 9306147A
Authority
MX
Mexico
Prior art keywords
tumor cells
growth
inhibit
pharmaceutical composition
transfected
Prior art date
Application number
MX9306147A
Other languages
English (en)
Inventor
Jeffrey A Ledbetter
Peter S Linsley
Lieping Chen
Ingegerd Hellstrom
Karl Erik Hellstrom
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX9306147A publication Critical patent/MX9306147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

La presente invención se refiere a un método para inhibir el crecimiento de células tumorales. Las células tumorales de un paciente se manipulan por ingeniería genética recombinante para que se expresen la proteína de superficie B7 y, después, estas células son readministradas al paciente. La presencia de la molécula B7 en la superficie de células tumorales, estimula una amplia respuesta inmunológica contra las células tumorales transfectadas con B7 (ó B7-transfectadas) y conta las células tumororales no transfectadas, lo cual da como resultado la muerte inmunológica de células tumorales localizadas y metastásicas. La B7-transfección de las células tumorales o membranas celulares, sirve como estimulante para inducir una potente respuesta inmunológica contra los antígenos de superficie presentes en las células tumorales.
MX9306147A 1992-10-02 1993-10-01 Composicion farmaceutica para inhibir el crecimiento de celulas tumorales. MX9306147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95612392A 1992-10-02 1992-10-02
US610293A 1993-01-15 1993-01-15

Publications (1)

Publication Number Publication Date
MX9306147A true MX9306147A (es) 1994-06-30

Family

ID=26675186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306147A MX9306147A (es) 1992-10-02 1993-10-01 Composicion farmaceutica para inhibir el crecimiento de celulas tumorales.

Country Status (11)

Country Link
US (1) US6183734B1 (es)
EP (1) EP0600591B1 (es)
JP (1) JP3837169B2 (es)
AT (1) ATE239073T1 (es)
AU (1) AU662450B2 (es)
CA (1) CA2107537C (es)
DE (1) DE69332921T2 (es)
DK (1) DK0600591T3 (es)
ES (1) ES2197147T3 (es)
MX (1) MX9306147A (es)
PT (1) PT600591E (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5056137A (en) * 1989-09-27 1991-10-08 Sills Richard R Method and apparatus for encoding and decoding signals
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
ES2176360T3 (es) * 1994-12-30 2002-12-01 Chiron Corp Combinacion de vehiculos de administracion de genes.
CA2172436A1 (en) * 1995-03-23 1996-09-24 Lieping Chen Compositions and methods for increasing the immunogenicity of tumor cells
DE19516040A1 (de) * 1995-05-04 1996-11-07 Boehringer Ingelheim Int Expression TAP und LMP in Tumorzellen
WO1996034952A1 (de) * 1995-05-04 1996-11-07 Boehringer Ingelheim International Gmbh Expression von tap und lmp in tumorzellen
SE9604581D0 (sv) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
US7235653B2 (en) 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6682741B1 (en) * 1998-06-10 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services β2 microglobulin fusion proteins and high affinity variants
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20030096016A1 (en) * 2001-09-07 2003-05-22 Yeda Research And Development Co. Ltd. Methods of kidney transplantation utilizing developing nephric tissue
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
WO2003092624A2 (en) * 2002-05-02 2003-11-13 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
CA2463464A1 (en) * 2003-04-28 2004-10-28 Auckland Uniservices Limited Methods of treatment and compositions therefor
US20050090440A1 (en) * 2003-04-28 2005-04-28 Krissansen Geoffrey W. Tumour treating combinations, compositions and methods
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508501A (ja) * 1990-07-02 1994-09-29 ブリストル―マイアーズ　スクイブ　カンパニー Ｂ細胞上のｃｄ２８レセプターに対するリガンドおよび該リガンドを用いた細胞間相互作用の調節方法

Also Published As

Publication number Publication date
US6183734B1 (en) 2001-02-06
AU4877293A (en) 1994-04-14
EP0600591A2 (en) 1994-06-08
ES2197147T3 (es) 2004-01-01
EP0600591A3 (en) 1995-03-01
EP0600591B1 (en) 2003-05-02
DE69332921T2 (de) 2004-05-19
CA2107537A1 (en) 1994-04-03
JPH0769928A (ja) 1995-03-14
JP3837169B2 (ja) 2006-10-25
PT600591E (pt) 2003-09-30
DK0600591T3 (da) 2003-08-25
AU662450B2 (en) 1995-08-31
CA2107537C (en) 2007-01-30
DE69332921D1 (de) 2003-06-05
ATE239073T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
MX9306147A (es) Composicion farmaceutica para inhibir el crecimiento de celulas tumorales.
LeBel et al. The major protein of pancreatic zymogen granule membranes (GP-2) is anchored via covalent bonds to phosphatidylinositol
TR199802789T2 (xx) Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
CL2004001483A1 (es) Procedimiento para producir una celula vegetal y un cultivo de estas, que son resistentes o tolerantes a un herbicida que inhibe a la glutamina sintetasa mediante la introduccion de un gen que codifica una acetil-transferasa; metodo para producir una
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
IE832394L (en) Immunogenic protein or peptide complex vaccine.
Plaut et al. Increase in histamine receptors on thymus-derived effector lymphocytes during the primary immune response to alloantigens
BR9814276A (pt) Antìgenos de superfìcie
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
MX9203439A (es) Una citocina mamifera, il-11
ES2094111T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen.
ES2058898T3 (es) Compuesto farmaceutico, util a titulo preventivo o curativo contra los tumores inducidos por los papilomavirus.
ES2141065T1 (es) Preparacion de vacunas subunitarias contra el virus sincitial respiratorio.
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
ES2054612T3 (es) Secuencias de adn que codifican para proteinas con actividad biologica de los inhibidores husi tipo-i y procedimientos tecnologicos geneticos para la preparacion de estas proteinas.
AR018489A1 (es) Uso de una celula realizada geneticamente que comprende dna que codifica una proteina de gen de activacion de linfocito 3 (lag-3) transmembrana y de dicha proteina para la fabricacion de un medicamento util para inducir la proteccion del rechazo de injerto y uso de moleculas antisentido de las misma
ATE290789T1 (de) Verwendungsmethoden von einkernigen phagozyten zur förderung der axonalen regeneration
ES2053472T3 (es) Procedimiento y reactivo para la determinacion de alfa-amilasa.
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
AR015230A1 (es) Composicion cosmetica que contiene un compuesto de actividad estimuladora de la produccion de interleuquina-6, cepa rhodotorula sebr 2002, procedimiento depreparacion de un extracto, composicion obtenida, utilizacion de un compuesto de actividad estimuladora y metodo de tratamiento cosmetico.
SE8900835D0 (sv) Improvement in or relating to organic compounds
Juretić et al. Helper effects required during in vivo priming for a cytolytic response to the HY antigen in nonresponder mice.
DK0740547T3 (da) Liposomer indeholdende deri indkapslede proteiner, fremgangsmåde til deres fremstilling, samt farmaceutiske og kosmetiske p